CARDIORENAL EFFECTS OF AN ORALLY ACTIVE DOPAMINE PRODRUG (TA-870) IN PATIENTS WITH CONGESTIVE HEART-FAILURE

被引：11

作者：

KUBOTA, J

KUBO, S

NISHIMURA, H

UEYAMA, M

KINO, M

NAKAYAMA, A

HARA, M

KAWAMURA, K

机构：

来源：

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY | 1989年 / 14卷 / 01期

关键词：

D O I：

10.1097/00005344-198907000-00010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：53 / 57

页数：5

共 18 条

[11] DOPAMINE AND THE KIDNEY [J].

LEE, MR .

CLINICAL SCIENCE, 1982, 62 (05) :439-448

[12] EFFECTS OF DOPAMINE IN MAN - AUGMENTATION OF SODIUM EXCRETION GLOMERULAR FILTRATION RATE + RENAL PLASMA FLOW [J].

MCDONALD, RH ;

MCNAY, JL ;

TUTTLE, EP ;

GOLDBERG, LI .

JOURNAL OF CLINICAL INVESTIGATION, 1964, 43 (06) :1116-&

[13]

MELLONI GF, 1979, CURR THER RES CLIN E, V25, P406

[14]

MORIMOTO S, 1968, FOLIA PHARMACOL JAP, V64, P123

[15]

SEELY FJ, 1967, ANN M AM SOC NEPHROL, P60

[16]

TANAKA K, 1985, JPN CLIN PHARM THER, V16, P259

[17] ENDOGENOUS CATECHOLAMINE LEVELS IN CHRONIC HEART-FAILURE - RELATION TO THE SEVERITY OF HEMODYNAMIC ABNORMALITIES [J].

VIQUERAT, CE ;

DALY, P ;

SWEDBERG, K ;

EVERS, C ;

CURRAN, D ;

PARMLEY, WW ;

CHATTERJEE, K .

AMERICAN JOURNAL OF MEDICINE, 1985, 78 (03) :455-460

[18]

1986, NEW PRODUCT INFORMAT

← 1 2 →